ArticleScience (New York, N.Y.)2015
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 235 papers.
0numbers the graph read from it
0cells of the map it votes in
235citing papers in PubMed
22.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
235 citing papers in PubMed, 292 citations in OpenAlex.
- Trial
- Candidate correlates of protection in the HVTN505 HIV-1 vaccine efficacy trial identified by positive-unlabeled learning.PLoS computational biology · 2025Trial
- Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.The Journal of infectious diseases · 2023Trial
- Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.The Journal of infectious diseases · 2022Trial
- Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.Vaccine · 2021Trial
- Vi-specific serological correlates of protection for typhoid fever.The Journal of experimental medicine · 2021Trial
- Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge.PLoS pathogens · 2020Trial
- Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.The Journal of clinical investigation · 2019Trial
- Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.Science translational medicine · 2019Trial
- Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells.Frontiers in immunology · 2019Trial
- Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).Lancet (London, England) · 2018Trial
- Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.The Journal of infectious diseases · 2017Trial
- Spatial Lipidomic Profiling of Kidney Functional Units in SIV-Infected and ART-Treated Rhesus Macaques.ACS measurement science au · 2026Article
- Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates.Journal of virology · 2026Article
- Article
- Fc effector functions in RNA viral infections: mechanisms of antiviral immunity and implications for vaccine design.Frontiers in immunology · 2026Review
- Current Approaches for Assessments of Neutralizing, Binding, and Effector Functions of Antibodies on the Path to Antibody-Mediated Prevention Strategies for HIV-1.Current HIV research · 2026Review
- Virus particle-based antibody-dependent cellular phagocytosis assay for HIV.Frontiers in immunology · 2026Article
- Quarantine-associated viral pathogens in non-human primates: pathobiology, diagnostic surveillance, control strategies, and one health implications.Frontiers in veterinary science · 2026Review
- ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primates.NPJ vaccines · 2025Article
175 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 11 institutions in 4 countries.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA. dbarouch@bidmc.harvard.edu.
Galit AlterRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA.
Thomas BrogeRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA.
Caitlyn LindeRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA.
Margaret E AckermanThayer School of Engineering at Dartmouth, Hanover, NH 03755, USA.
Eric P BrownThayer School of Engineering at Dartmouth, Hanover, NH 03755, USA.
Erica N BorducchiCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Kaitlin M SmithCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Joseph P NkololaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Jinyan LiuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Jennifer ShieldsCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Lily ParenteauCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
James B WhitneyCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Peter AbbinkCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
David M Ng'ang'aCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Christy L LavineCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
James R PerryCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Wenjun LiUniversity of Massachusetts Medical School, Worcester, MA 01605, USA.
Arnaud D ColantonioNew England Primate Research Center, Southborough, MA 01772, USA.
Mark G LewisBioqual, Rockville, MD 20852, USA.
Bing ChenChildren's Hospital, Boston, MA 02115, USA.
Holger WenschuhJPT Peptide Technologies GmbH, 12489 Berlin, Germany.
Ulf ReimerJPT Peptide Technologies GmbH, 12489 Berlin, Germany.
Michael PiatakAIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD 21702, USA.
Jeffrey D LifsonAIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD 21702, USA.
Scott A HandleyWashington University School of Medicine, St. Louis, MO 63110, USA.
Herbert W VirginWashington University School of Medicine, St. Louis, MO 63110, USA.
Marguerite KoutsoukosGSK Vaccines, 1330 Rixensart, Belgium.
Clarisse LorinGSK Vaccines, 1330 Rixensart, Belgium.
Gerald VossGSK Vaccines, 1330 Rixensart, Belgium.
Mo WeijtensJanssen Infectious Diseases and Vaccines (formerly Crucell), 2301 Leiden, Netherlands.
Maria G PauJanssen Infectious Diseases and Vaccines (formerly Crucell), 2301 Leiden, Netherlands.
Hanneke SchuitemakerJanssen Infectious Diseases and Vaccines (formerly Crucell), 2301 Leiden, Netherlands.
Beth Israel Deaconess Medical Center · USGlaxoSmithKline (Belgium) · BEJanssen (Netherlands) · NLRagon Institute of MGH, MIT and Harvard · USDartmouth College · USJPT Peptide Technologies (Germany) · DELeidos (United States) · USWashington University in St. Louis · USBioqual · USBoston Children's Hospital · USUniversity of Massachusetts Chan Medical School · US
Funding
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4MPreclinical Evaluation of Novel Adenovirus Prime-Boost HIV-1 VaccineU19AI078526 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2008 to 2012
$44.0MVirologyU19AI095985 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BURTON, DENNIS R. · 2011 to 2015
$35.9MPreclinical Evaluation of Novel Ad/MVA and Ad/Protein HIV-1 VaccinesU19AI096040 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SEAMAN, MICHAEL SCOTT · 2012 to 2016
$18.0MDemystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8MDemystifying the antiviral activity of the IgG3+ antibody responseR01AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI JUELG, BORIS DOMINIK · 2009 to 2024
$4.1MImpact of HIV Envelope Conformation on ImmunogenicityR01AI084794 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., CHEN, BING · 2009 to 2013
$4.0MTuning Fc-effector functions of HIV-specific antibodiesR01AI102660 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2012 to 2015
$3.0MMETAGENOMICS OF ENTERIC DISEASE IN SIV-INFECTED AND UNINFECTED MACAQUESR01OD011170 · OD · WASHINGTON UNIVERSITY · PI BAROUCH, DAN H., VIRGIN, HERBERT W · 2012 to 2014
$2.3MApplying High-Performance Protein Engineering Tools to HIV Immunogen DesignR01AI102691 · NIAID · DARTMOUTH COLLEGE · PI ACKERMAN, MARGARET E · 2012 to 2015
$2.2MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS AI060354NIAID NIH HHS AI078526NIAID NIH HHS AI080289NIAID NIH HHS AI084794NIAID NIH HHS AI095985NIAID NIH HHS AI096040NIAID NIH HHS AI102660NIAID NIH HHS AI102691NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI080289NIAID NIH HHS R01 AI084794NIAID NIH HHS R01 AI102660NIAID NIH HHS R01 AI102691NIAID NIH HHS R37 AI080289NIAID NIH HHS U19 AI078526NIAID NIH HHS U19 AI095985NIAID NIH HHS U19 AI096040NIH HHS OD011170NIH HHS R01 OD011170
Abstract
Preclinical studies of viral vector-based HIV-1 vaccine candidates have previously shown partial protection against neutralization-resistant virus challenges in rhesus monkeys. In this study, we evaluated the protective efficacy of adenovirus serotype 26 (Ad26) vector priming followed by purified envelope (Env) glycoprotein boosting. Rhesus monkeys primed with Ad26 vectors expressing SIVsmE543 Env, Gag, and Pol and boosted with AS01B-adjuvanted SIVmac32H Env gp140 demonstrated complete protection in 50% of vaccinated animals against a series of repeated, heterologous, intrarectal SIVmac251 challenges that infected all controls. Protective efficacy correlated with the functionality of Env-specific antibody responses. Comparable protection was also observed with a similar Ad/Env vaccine against repeated, heterologous, intrarectal SHIV-SF162P3 challenges. These data demonstrate robust protection by Ad/Env vaccines against acquisition of neutralization-resistant virus challenges in rhesus monkeys.
Indexed as
Adenovirus VaccinesAdoptive TransferAIDS VaccinesAnimalsAntibodies, NeutralizingFemaleGene Products, envGene Products, gagGene Products, polGenetic VectorsHistocompatibility Antigens Class IHIV-1Immunization, SecondaryMacaca mulattaMaleSAIDS VaccinesAdenovirus VaccinesAIDS VaccinesAntibodies, NeutralizingGene Products, envGene Products, gagGene Products, polHistocompatibility Antigens Class ISAIDS Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.